A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine‐refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) ‐Targeted Therapy. The gene discussed is KDR; the disease is thyroid gland carcinoma.